Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: adenosine A2 receptor antagonists - Almirall SA/Neurocrine Biosciences

Drug Profile

Research programme: adenosine A2 receptor antagonists - Almirall SA/Neurocrine Biosciences

Alternative Names: NBI 80649

Latest Information Update: 28 Feb 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Almirall-Prodesfarma; Neurocrine Biosciences
  • Developer Almirall S.A.; Neurocrine Biosciences
  • Class Small molecules
  • Mechanism of Action Adenosine A2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Huntington's disease; Parkinson's disease

Most Recent Events

  • 28 Feb 2011 Development discontinued for Huntington's disease before 2011
  • 28 Feb 2011 Development discontinued for Parkinson's disease before 2011
  • 07 Nov 2007 Pharmacodynamics and adverse events data from a preclinical study in Parkinson's disease presented at the 37th Annual Meeting of the Society for Neuroscience (SfN-2007)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top